TCBP - TC Biopharm receives approval from UK health agency to begin leukemia therapy trials

TC Biopharm (NASDAQ:TCBP) said it received approvals from the U.K. health agency MHRA, and research ethics committee to begin trials of cell therapy OmnImmune to treat acute myeloid leukemia (AML). The company added that the phase 2/3 trials will begin enrollment in H1 in the U.K., with expansion into the U.S. following shortly thereafter. OmnImmune is a cell therapy that consists of activated and expanded gamma delta T cells and has received orphan drug designation for the treatment. AML is a cancer that affects the blood and bone marrow and progresses rapidly, resulting in an abnormal increase in a type of white blood cells.

For further details see:

TC Biopharm receives approval from UK health agency to begin leukemia therapy trials